Welcome to our dedicated page for TRINET GROUP SEC filings (Ticker: TNET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TriNet Group, Inc. filings document the company’s HR and human capital management business for small and medium-size businesses, including operating results, financial condition, guidance-related disclosures, and non-GAAP reconciliations furnished with earnings releases.
The company’s regulatory record includes 8-K reports for quarterly results, dividends, stock repurchase activity, and other material events. Proxy filings document governance matters, shareholder voting items, board and executive compensation disclosures, while capital-structure disclosures address common-stock dividends, repurchase authorizations, and related shareholder-return actions.
TRINET GROUP, INC. (TNET) Form 4: Director Paul Edward Chamberlain sold 600 shares of the issuer's common stock on 08/07/2025 at a reported price of $64.18 per share. The filing states the sale was effected pursuant to a 10b5-1 trading plan established by the reporting person on November 26, 2024. After the reported transaction, the reporting person beneficially owns 38,440 shares, a figure that the filer says includes unvested restricted stock units. The Form 4 was signed by an attorney-in-fact, Sheryl Southwick, on 08/11/2025. This disclosure records a routine insider sale under a prearranged plan and the remaining beneficial ownership reported by the director.
TriNet (TNET) Q2 2025 10-Q highlights: Total revenue was nearly flat at $1.24 B as 4% fewer average work-site employees (WSEs) were offset by higher pricing on professional and insurance services. Professional Service Revenue fell 8% to $172 M, while Insurance Service Revenue inched up 1% to $1.05 B. Rising medical utilization and specialty-drug spend lifted insurance costs 3%, pushing the Insurance Cost Ratio to 90% (vs. 88% LY). Operating expenses declined 2%, yet margin pressure drove income before tax down 37% to $51 M and net income down 38% to $37 M; diluted EPS slid to $0.77 from $1.20. Adjusted EBITDA dropped 23% to $105 M and margin narrowed to 8.5%.
Operational & liquidity points: Average WSEs fell 4% to 336,010 as client attrition and softer hiring hit the Technology, Professional Services, Main Street and Life Sciences verticals; co-employed WSEs declined 8% while platform-only users rose 56%. YTD operating cash flow improved 31% to $170 M, aiding a 13% rise in cash to $407 M and a 28% lift in corporate working capital to $254 M. Debt remained $984 M; the $90 M revolver balance was repaid in July. The company repurchased 1.23 M shares for $91 M (-92) and paid two $0.275 dividends, leaving $160 M available under its buyback authorization. Management continues a restructuring program (Q2 charge $2 M) and is assessing tax changes under the July 4 2025 OBBBA. All debt covenants were met.